Clinical Trials Browser

Has announcements × zanubrutinib × Clear all

NCT03336333 2026-03-09

SEQUOIA

Phase 3 Active not recruiting

590 enrolled 12 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03332017 2026-02-18

ROSEWOOD

Phase 2 Completed

217 enrolled 23 charts 1 FDA

Lymphoma, Follicular

NCT03734016 2025-03-30

ALPINE

Phase 3 Completed

652 enrolled 27 charts 1 FDA

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03053440 2024-10-26

ASPEN

Phase 3 Completed

201 enrolled 19 charts 1 FDA

Waldenstrom Macroglobulinemia

NCT03206970 2024-10-26

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Phase 2 Completed

86 enrolled 16 charts 1 FDA

Lymphoma, Mantle-Cell

NCT03846427 2024-10-26

MAGNOLIA

Phase 2 Completed

68 enrolled 28 charts 1 FDA

Lymphoma, B-Cell, Marginal Zone

NCT02343120 2022-04-28

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Phase 1/2 Completed

385 enrolled 29 charts 2 FDA

B-cell Malignancies